Eli Lilly Diversifies Beyond GLP-1s with Strategic Pipeline Expansion and M&A

While Eli Lilly (NYSE: LLY) continues to dominate the anti-obesity market with Zepbound and Mounjaro, the pharmaceutical giant is aggressively diversifying its revenue streams to mitigate future competition. By expanding its therapeutic reach, the company aims to protect its pricing power as newer anti-obesity therapies enter the market. The company is shifting focus toward a multi-pillar growth strategy, reducing reliance on GLP-1 therapies by scaling its presence in oncology and neuroscience. This diversification provides a competitive edge over rivals like Novo Nordisk, which remains more heavily concentrated in diabetes and weight loss products. Beyond obesity, Lilly's portfolio includes Verzenio, which generated $5.7 billion in sales last year, representing an 8% year-over-year increase. Similarly, the immunosuppressant Taltz saw a 9% increase in sales, reaching $3.6 billion. The company is also scaling newer treatments including Kisunla for Alzheimer's, Jaypirca for cancer, and Ebglyss for eczema. To bolster its genetic medicine capabilities, Lilly recently announced the acquisition of Kelonia Therapeutics for $3.25 billion in cash, with a total potential equity value of up to $7 billion. This move follows the 2025 acquisition of Verve Therapeutics, signaling a long-term commitment to gene therapy and advanced cancer treatments to ensure sustainable growth across multiple medical fields.